About Ind Swift Laboratories Limited
Data last updated: 14 July 2026
Ind Swift Laboratories Limited is a public limited company based in Chandigarh, Chandigarh, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 04 January 1995, the company has been in operation for over 31 years.
Registered with ROC Chandigarh under CIN L24232CH1995PLC015553. Listed on BSE: 532305 and NSE: INDSWFTLAB.
Capital: an authorised share capital of ₹140 Cr and a paid-up capital of ₹86.96 Cr. It is led by directors including Rishav Mehta and Himanshu Jain.
Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: Sco 850 Shivalik Enclave Nac Manimajra, Chandigarh, Chandigarh, India – 160101.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹641.29 Cr, a growth of 14.17% compared to the previous year. The net worth stands at ₹1,383.97 Cr (up 17.99% YoY). Total assets are valued at ₹1,673.35 Cr (up 16.34% YoY).
Its group structure includes 2 subsidiaries.
The company is associated with 1 brand - Ind Swift. As per MCA filings, the company has open charges of ₹827.92 Cr and satisfied charges of ₹5,103.76 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website indswiftlabs.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressSco 850 Shivalik Enclave Nac Manimajra, Chandigarh, Chandigarh, India – 160101
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Ind Swift Laboratories Limited
Ind Swift Laboratories Limited has one previous CIN (Corporate Identification Number): U24232CH1995PLC015553. The current CIN is L24232CH1995PLC015553, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232CH1995PLC015553 | Current |
| U24232CH1995PLC015553 | Previous |
Associated Brands with Ind Swift Laboratories Limited
Ind Swift Laboratories Limited operates one associated brand: Ind Swift. These brands represent Ind Swift Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| API CDMO also having capabilities to manufacture HPAPIs and intermediates | indswiftlabs.com |
Competitors & Alternatives of Ind Swift Laboratories Limited
Brands and companies operating in the same space as Ind Swift Laboratories Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Ind Swift Laboratories Limited
Ind Swift Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Ind Swift Laboratories Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Ind Swift Laboratories Limited
Ind Swift Laboratories Limited is audited by Rattan Kaur and Associates (ICAI peer reviewed, certificate valid till 2027-01-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Rattan Kaur and Associates (ICAI peer reviewed, certificate valid till 2027-01-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Ind Swift Laboratories Limited
Ind Swift Laboratories Limited is currently managed by 8 directors, with 26 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Rishav Mehta
Also directs:
Essix Biosciences Limited, Vibrant Agro Industries Limited
|
Whole-Time Director | 23 Mar 2010 | 16 Years 4 Months | Current |
| Himanshu Jain | Whole-Time Director | 04 Jan 1995 | 31 Years 7 Months | Current |
| Sahil Munjal | Whole-Time Director | 13 Feb 2020 | 6 Years 6 Months | Current |
| Neerja Chathley | Director | 10 May 2019 | 7 Years 3 Months | Current |
| Rajinder Kumar Gupta | Director | 23 Jun 2021 | 5 Years 1 Months | Current |
|
Navrattan Munjal
Also directs:
Mjm Remedies Private Limited, Essix Biosciences Limited, Nimbua Greenfield (Punjab) Association and 1 more
|
Managing Director | 04 Jan 1995 | 31 Years 7 Months | Current |
Financials of Ind Swift Laboratories Limited FY 2026 filings available
Ind Swift Laboratories Limited reported revenue of ₹641.29 Cr (up 14.17% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹641.29 Cr | ₹561.71 Cr | ₹1,280.9 Cr | ₹1,207.31 Cr | ₹1,038.73 Cr | ₹779.64 Cr |
| Other Income | ₹46.97 Cr | ₹81.38 Cr | ₹45.37 Cr | ₹33.5 Cr | ₹42.71 Cr | ₹33.4 Cr |
| Total Income | ₹688.26 Cr | ₹643.09 Cr | ₹1,326.27 Cr | ₹1,240.81 Cr | ₹1,081.45 Cr | ₹813.04 Cr |
| Cost of Materials Consumed | ₹271.74 Cr | ₹224.2 Cr | ₹599.06 Cr | ₹657.46 Cr | ₹565 Cr | ₹409.1 Cr |
| Purchases of Stock-in-Trade | ₹37.66 Cr | ₹70.8 Cr | ₹25.33 Cr | ₹10.46 Cr | ₹1.06 Cr | ₹0 |
| Changes in Inventories | -₹26.94 Cr | -₹7.05 Cr | ₹37.07 Cr | -₹12.34 Cr | -₹39.47 Cr | -₹12.44 Cr |
| Employee Benefit Expense | ₹137.98 Cr | ₹117.52 Cr | ₹152.81 Cr | ₹135.84 Cr | ₹114.35 Cr | ₹102.72 Cr |
| Finance Costs | ₹1.4 Cr | ₹2.92 Cr | ₹51.1 Cr | ₹92.17 Cr | ₹95.53 Cr | ₹107.49 Cr |
| Depreciation & Amortisation | ₹30.61 Cr | ₹24.48 Cr | ₹53.3 Cr | ₹57.36 Cr | ₹131.04 Cr | ₹90.06 Cr |
| Other Expenses | ₹175.77 Cr | ₹175.63 Cr | ₹212.42 Cr | ₹186.69 Cr | ₹201.4 Cr | ₹135.88 Cr |
| Total Expenses | ₹628.21 Cr | ₹608.5 Cr | ₹1,131.1 Cr | ₹1,127.64 Cr | ₹1,068.92 Cr | ₹832.81 Cr |
| Profit Before Exceptional Items & Tax | ₹60.05 Cr | ₹34.59 Cr | ₹195.17 Cr | ₹113.17 Cr | ₹12.53 Cr | -₹19.77 Cr |
| Exceptional Items | -₹11.01 Cr | ₹223.2 Cr | ₹386.59 Cr | -₹26.65 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹49.05 Cr | ₹257.8 Cr | ₹581.76 Cr | ₹86.52 Cr | ₹12.53 Cr | -₹19.77 Cr |
| Total Tax Expense | ₹7.73 Cr | ₹7.27 Cr | ₹151.27 Cr | ₹38.69 Cr | ₹14.68 Cr | ₹1.42 Cr |
| Net Profit | ₹41.42 Cr | ₹250.48 Cr | ₹421.45 Cr | ₹47.6 Cr | -₹2.15 Cr | -₹21.19 Cr |
| attributable to Owners | ₹0 | ₹0 | ₹0 | ₹0 | - | - |
| attributable to NCI | ₹0 | ₹0 | ₹0 | ₹0 | - | - |
| Other Comprehensive Income | -₹87.45 Lakh | ₹17.23 Cr | ₹34.7 Lakh | ₹31.94 Lakh | -₹42.54 Lakh | ₹5.22 Lakh |
| Total Comprehensive Income | ₹40.54 Cr | ₹267.7 Cr | ₹421.8 Cr | ₹47.92 Cr | -₹2.57 Cr | -₹21.14 Cr |
| EBITDA (computed) | ₹92.06 Cr | ₹61.99 Cr | ₹299.57 Cr | ₹262.7 Cr | ₹239.1 Cr | ₹177.78 Cr |
| Basic EPS | ₹4.95 | ₹37.25 | ₹71.24 | ₹8.06 | ₹-0.36 | ₹-4.28 |
| Diluted EPS | ₹4.84 | ₹35.21 | ₹71.24 | ₹8.06 | ₹-0.36 | ₹-4.28 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,673.35 Cr | ₹1,438.34 Cr | ₹1,165.11 Cr | ₹1,824.06 Cr |
| Non-current Assets | ₹696.6 Cr | ₹572.99 Cr | ₹503.98 Cr | ₹659.55 Cr |
| Current Assets | ₹976.75 Cr | ₹865.35 Cr | ₹661.13 Cr | ₹1,164.52 Cr |
| Property, Plant & Equipment | ₹275.14 Cr | ₹260.07 Cr | ₹5.36 Cr | ₹583.19 Cr |
| Inventories | ₹147.93 Cr | ₹114.18 Cr | ₹10.46 Cr | ₹438.6 Cr |
| Trade Receivables | ₹198.55 Cr | ₹164.52 Cr | ₹169.12 Cr | ₹505.32 Cr |
| Cash & Equivalents | ₹429.85 Cr | ₹428.04 Cr | ₹431.93 Cr | ₹18.2 Cr |
| Equity (Net Worth) | ₹1,383.97 Cr | ₹1,172.97 Cr | ₹931.44 Cr | ₹681.93 Cr |
| Equity Share Capital | ₹86.84 Cr | ₹68.74 Cr | ₹59.09 Cr | ₹59.81 Cr |
| Borrowings (Non-current) | ₹12.3 Cr | ₹25.71 Cr | ₹11.16 Cr | ₹752.6 Cr |
| Borrowings (Current) | ₹5.61 Cr | ₹14.91 Cr | ₹5.46 Cr | ₹108.94 Cr |
| Total Debt (computed) | ₹17.91 Cr | ₹40.61 Cr | ₹16.62 Cr | ₹861.54 Cr |
| Current Liabilities | ₹254.7 Cr | ₹220.58 Cr | ₹221.28 Cr | ₹371.09 Cr |
| Total Liabilities | ₹289.38 Cr | ₹265.37 Cr | ₹233.67 Cr | ₹1,142.13 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹63.18 Cr | -₹25.47 Cr | -₹180.87 Cr | ₹194.62 Cr | ₹150.27 Cr |
| Investing Cash Flow | -₹72.68 Cr | -₹109.62 Cr | -₹104.32 Cr | -₹13.37 Cr | ₹4.77 Cr |
| Financing Cash Flow | ₹141.81 Cr | ₹69.2 Cr | ₹698.91 Cr | -₹185.66 Cr | -₹140.88 Cr |
| Capital Expenditure | ₹87.72 Cr | ₹64.41 Cr | ₹44.52 Cr | ₹12.77 Cr | ₹18.41 Cr |
| Free Cash Flow (computed) | -₹150.9 Cr | -₹89.88 Cr | -₹225.38 Cr | ₹181.85 Cr | ₹131.86 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹11.44 Cr | -₹66.47 Cr | ₹413.28 Cr | -₹4.41 Cr | ₹14.17 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹169.79 Cr | ₹150.85 Cr | ₹152.64 Cr | ₹152.73 Cr | ₹138.24 Cr | ₹8.66 Cr | ₹11.96 Cr | ₹33.17 Cr | ₹393.33 Cr | ₹287.51 Cr | ₹289.71 Cr | ₹310.34 Cr |
| Other Income | ₹2.22 Cr | ₹27.58 Cr | ₹17.86 Cr | ₹14.58 Cr | ₹4.46 Cr | ₹13.81 Cr | ₹13.01 Cr | ₹11.14 Cr | ₹25.25 Cr | ₹7.11 Cr | ₹7.4 Cr | ₹5.61 Cr |
| Total Income | ₹172.01 Cr | ₹178.43 Cr | ₹170.5 Cr | ₹167.32 Cr | ₹142.7 Cr | ₹22.48 Cr | ₹24.96 Cr | ₹44.31 Cr | ₹418.59 Cr | ₹294.63 Cr | ₹297.11 Cr | ₹315.94 Cr |
| Cost of Materials Consumed | ₹74.2 Cr | ₹66.03 Cr | ₹66.1 Cr | ₹65.4 Cr | ₹16.25 Cr | ₹5.85 Cr | ₹7.81 Cr | ₹2.13 Cr | ₹247.98 Cr | ₹163.1 Cr | ₹144.18 Cr | ₹145.69 Cr |
| Purchases of Stock-in-Trade | ₹7.26 Cr | ₹9.85 Cr | ₹11.89 Cr | ₹8.66 Cr | ₹33.91 Cr | ₹36.73 Lakh | ₹49.85 Lakh | ₹25.18 Cr | ₹21.2 Cr | ₹1.76 Cr | ₹3.84 Cr | ₹10.46 Cr |
| Changes in Inventories | -₹19.98 Cr | -₹5.64 Cr | -₹34.71 Lakh | -₹97.32 Lakh | ₹7.54 Cr | ₹0 | ₹0 | ₹0 | ₹43.96 Cr | -₹9.43 Cr | -₹3.58 Cr | ₹6.11 Cr |
| Employee Benefit Expense | ₹37.22 Cr | ₹31.95 Cr | ₹36.27 Cr | ₹32.53 Cr | ₹31.32 Cr | ₹6.7 Cr | ₹5.8 Cr | ₹6.09 Cr | ₹39.25 Cr | ₹37.08 Cr | ₹37.46 Cr | ₹39.02 Cr |
| Finance Costs | -₹2.43 Cr | ₹67.37 Lakh | ₹2.01 Cr | ₹1.15 Cr | -₹26.76 Cr | ₹11.4 Lakh | ₹41.12 Lakh | ₹16.88 Lakh | -₹11.47 Cr | ₹21.05 Cr | ₹21.14 Cr | ₹20.38 Cr |
| Depreciation & Amortisation | ₹8.12 Cr | ₹8.84 Cr | ₹6.98 Cr | ₹6.68 Cr | ₹7.44 Cr | ₹24.59 Lakh | ₹21.65 Lakh | ₹24.99 Lakh | ₹12.67 Cr | ₹13.56 Cr | ₹13.19 Cr | ₹13.89 Cr |
| Other Expenses | ₹50.52 Cr | ₹44.48 Cr | ₹37.25 Cr | ₹43.51 Cr | ₹58.4 Cr | ₹10.28 Cr | ₹9.63 Cr | ₹9.51 Cr | ₹78.25 Cr | ₹43.73 Cr | ₹42.11 Cr | ₹48.76 Cr |
| Total Expenses | ₹154.9 Cr | ₹156.19 Cr | ₹160.16 Cr | ₹156.96 Cr | ₹128.11 Cr | ₹23.56 Cr | ₹24.38 Cr | ₹43.33 Cr | ₹431.84 Cr | ₹270.85 Cr | ₹258.34 Cr | ₹284.31 Cr |
| Profit Before Exceptional Items & Tax | ₹17.11 Cr | ₹22.25 Cr | ₹10.34 Cr | ₹10.35 Cr | ₹14.58 Cr | -₹1.08 Cr | ₹58.36 Lakh | ₹98 Lakh | -₹13.25 Cr | ₹23.78 Cr | ₹38.77 Cr | ₹31.64 Cr |
| Exceptional Items | -₹5.15 Cr | -₹5.85 Cr | ₹0 | ₹0 | ₹215.88 Cr | ₹0 | ₹0 | ₹0 | ₹386.59 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹11.96 Cr | ₹16.39 Cr | ₹10.34 Cr | ₹10.35 Cr | ₹230.46 Cr | -₹1.08 Cr | ₹58.36 Lakh | ₹98 Lakh | ₹373.34 Cr | ₹23.78 Cr | ₹38.77 Cr | ₹31.64 Cr |
| Total Tax Expense | -₹3.15 Cr | ₹4 Cr | ₹2.3 Cr | ₹1.71 Cr | ₹8.19 Cr | -₹1.08 Cr | ₹18.45 Lakh | -₹2.88 Lakh | ₹134.47 Cr | ₹4.25 Cr | ₹6.93 Cr | ₹5.62 Cr |
| Net Profit | ₹15.11 Cr | ₹9.54 Cr | ₹7.99 Cr | ₹8.77 Cr | ₹222.27 Cr | ₹62,000 | ₹41.33 Lakh | ₹93.56 Lakh | ₹238.87 Cr | ₹19.42 Cr | ₹31.66 Cr | ₹17.24 Cr |
| attributable to Owners | ₹0 | - | - | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| attributable to NCI | ₹0 | - | - | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | -₹87.45 Lakh | ₹0 | ₹0 | ₹0 | ₹17.23 Cr | ₹0 | ₹0 | ₹0 | -₹2.78 Lakh | ₹0 | -₹37.48 Lakh | ₹0 |
| Total Comprehensive Income | ₹14.24 Cr | ₹9.54 Cr | ₹7.99 Cr | ₹8.77 Cr | ₹239.49 Cr | ₹62,000 | ₹41.33 Lakh | ₹93.56 Lakh | ₹238.84 Cr | ₹19.42 Cr | ₹31.28 Cr | ₹17.24 Cr |
| EBITDA (computed) | ₹22.79 Cr | ₹31.76 Cr | ₹19.34 Cr | ₹18.18 Cr | -₹4.74 Cr | -₹72.14 Lakh | ₹1.21 Cr | ₹1.4 Cr | -₹12.05 Cr | ₹58.39 Cr | ₹73.09 Cr | ₹65.91 Cr |
| Basic EPS | ₹1.81 | ₹1.17 | ₹1.00 | ₹1.28 | ₹32.96 | ₹0.00 | ₹0.07 | ₹0.16 | ₹40.42 | ₹3.29 | ₹5.36 | ₹2.92 |
| Diluted EPS | ₹1.76 | ₹1.13 | ₹0.96 | ₹1.17 | ₹30.08 | ₹0.00 | ₹0.07 | ₹0.16 | ₹40.42 | ₹3.29 | ₹5.36 | ₹2.92 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹635.89 Cr | ₹549.65 Cr | ₹1,227.32 Cr | ₹1,151.96 Cr | ₹988.09 Cr | ₹856.58 Cr | ₹751.84 Cr |
| Other Income | ₹46.96 Cr | ₹81.27 Cr | ₹45.31 Cr | ₹33.28 Cr | ₹41.72 Cr | ₹23.13 Cr | ₹36.02 Cr |
| Total Income | ₹682.84 Cr | ₹630.92 Cr | ₹1,272.63 Cr | ₹1,185.24 Cr | ₹1,029.81 Cr | ₹879.71 Cr | ₹787.86 Cr |
| Cost of Materials Consumed | ₹274.74 Cr | ₹224.56 Cr | ₹561.18 Cr | ₹618.72 Cr | ₹525.73 Cr | ₹427.47 Cr | ₹391.29 Cr |
| Purchases of Stock-in-Trade | ₹37.66 Cr | ₹70.8 Cr | ₹25.33 Cr | ₹10.46 Cr | ₹1.06 Cr | ₹0 | ₹0 |
| Changes in Inventories | -₹28.91 Cr | -₹10.36 Cr | ₹37.07 Cr | -₹12.34 Cr | -₹39.47 Cr | -₹2.48 Cr | -₹12.44 Cr |
| Employee Benefit Expense | ₹136.33 Cr | ₹115.33 Cr | ₹148.88 Cr | ₹132.7 Cr | ₹111.88 Cr | ₹104.17 Cr | ₹100.38 Cr |
| Finance Costs | ₹1.4 Cr | ₹2.92 Cr | ₹51.1 Cr | ₹92.17 Cr | ₹95.53 Cr | ₹100.22 Cr | ₹107.48 Cr |
| Depreciation & Amortisation | ₹30.57 Cr | ₹24.48 Cr | ₹53.3 Cr | ₹57.36 Cr | ₹130.97 Cr | ₹87.29 Cr | ₹90.06 Cr |
| Other Expenses | ₹169.83 Cr | ₹162.25 Cr | ₹204.89 Cr | ₹180.33 Cr | ₹194.42 Cr | ₹146.92 Cr | ₹130.66 Cr |
| Total Expenses | ₹621.62 Cr | ₹589.98 Cr | ₹1,081.75 Cr | ₹1,079.39 Cr | ₹1,020.12 Cr | ₹863.59 Cr | ₹807.42 Cr |
| Profit Before Exceptional Items & Tax | ₹61.22 Cr | ₹40.94 Cr | ₹190.88 Cr | ₹105.85 Cr | ₹9.69 Cr | ₹16.12 Cr | -₹19.56 Cr |
| Exceptional Items | -₹11.01 Cr | ₹223.2 Cr | ₹386.59 Cr | -₹26.65 Cr | -₹1.69 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹50.22 Cr | ₹264.14 Cr | ₹577.47 Cr | ₹79.2 Cr | ₹8 Cr | ₹16.12 Cr | -₹19.56 Cr |
| Total Tax Expense | ₹7.66 Cr | ₹8.06 Cr | ₹169.86 Cr | ₹36.73 Cr | ₹13.7 Cr | ₹20.52 Cr | ₹1.23 Cr |
| Net Profit | ₹42.56 Cr | ₹256.09 Cr | ₹418.39 Cr | ₹42.47 Cr | -₹5.71 Cr | -₹4.4 Cr | -₹20.79 Cr |
| Other Comprehensive Income | -₹87.45 Lakh | ₹17.23 Cr | -₹34.7 Lakh | ₹31.94 Lakh | -₹42.54 Lakh | -₹1.52 Cr | ₹5.22 Lakh |
| Total Comprehensive Income | ₹41.68 Cr | ₹273.31 Cr | ₹418.04 Cr | ₹42.79 Cr | -₹6.13 Cr | -₹5.92 Cr | -₹20.74 Cr |
| EBITDA (computed) | ₹93.19 Cr | ₹68.34 Cr | ₹295.28 Cr | ₹255.37 Cr | ₹236.19 Cr | ₹203.62 Cr | ₹177.98 Cr |
| Basic EPS | ₹5.09 | ₹38.08 | ₹70.81 | ₹7.19 | ₹-0.97 | ₹-0.74 | ₹-4.20 |
| Diluted EPS | ₹4.97 | ₹36.00 | ₹70.81 | ₹7.19 | ₹-0.97 | ₹-0.74 | ₹-4.20 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,654.34 Cr | ₹1,422.05 Cr | ₹1,104.79 Cr | ₹1,788.27 Cr |
| Non-current Assets | ₹779.43 Cr | ₹628.32 Cr | ₹559.25 Cr | ₹714.2 Cr |
| Current Assets | ₹874.91 Cr | ₹793.73 Cr | ₹545.54 Cr | ₹1,072.67 Cr |
| Property, Plant & Equipment | ₹275.14 Cr | ₹258.84 Cr | ₹5.32 Cr | ₹583.15 Cr |
| Inventories | ₹142.98 Cr | ₹107.25 Cr | ₹0 | ₹427.54 Cr |
| Trade Receivables | ₹188.77 Cr | ₹160.23 Cr | ₹106.6 Cr | ₹469.49 Cr |
| Cash & Equivalents | ₹414.99 Cr | ₹413.01 Cr | ₹425.73 Cr | ₹9.96 Cr |
| Equity (Net Worth) | ₹1,370.7 Cr | ₹1,164.08 Cr | ₹922.24 Cr | ₹675.35 Cr |
| Equity Share Capital | ₹86.84 Cr | ₹68.74 Cr | ₹59.09 Cr | ₹59.81 Cr |
| Borrowings (Non-current) | ₹12.11 Cr | ₹22.54 Cr | ₹3 Cr | ₹744.97 Cr |
| Borrowings (Current) | ₹5.61 Cr | ₹14.62 Cr | ₹5.32 Cr | ₹108.79 Cr |
| Total Debt (computed) | ₹17.72 Cr | ₹37.16 Cr | ₹8.31 Cr | ₹853.75 Cr |
| Current Liabilities | ₹251.55 Cr | ₹216.35 Cr | ₹178.32 Cr | ₹350.05 Cr |
| Total Liabilities | ₹283.64 Cr | ₹257.97 Cr | ₹182.54 Cr | ₹1,112.93 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹40.19 Cr | -₹39.15 Cr | -₹179.77 Cr | ₹182.67 Cr | ₹136.26 Cr |
| Investing Cash Flow | -₹100.16 Cr | -₹109.67 Cr | -₹104.32 Cr | -₹13.69 Cr | ₹2.76 Cr |
| Financing Cash Flow | ₹145.26 Cr | ₹74.22 Cr | ₹699.86 Cr | -₹168.41 Cr | -₹139.59 Cr |
| Capital Expenditure | ₹87.72 Cr | ₹64.41 Cr | ₹44.52 Cr | ₹13.27 Cr | ₹18.38 Cr |
| Free Cash Flow (computed) | -₹127.92 Cr | -₹103.56 Cr | -₹224.28 Cr | ₹169.4 Cr | ₹117.88 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹4.9 Cr | -₹74.6 Cr | ₹415.77 Cr | ₹57.72 Lakh | -₹57.26 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹172.7 Cr | ₹149.48 Cr | ₹150.44 Cr | ₹147.99 Cr | ₹144.75 Cr | ₹1.41 Cr | ₹2.71 Cr | ₹30.46 Cr | ₹381.73 Cr | ₹276.28 Cr | ₹270.3 Cr | ₹299.01 Cr |
| Other Income | ₹2.21 Cr | ₹27.58 Cr | ₹17.86 Cr | ₹14.58 Cr | ₹4.41 Cr | ₹13.81 Cr | ₹12.95 Cr | ₹11.14 Cr | ₹25.25 Cr | ₹7.11 Cr | ₹7.4 Cr | ₹5.55 Cr |
| Total Income | ₹174.91 Cr | ₹177.06 Cr | ₹168.3 Cr | ₹162.58 Cr | ₹149.16 Cr | ₹15.22 Cr | ₹15.65 Cr | ₹41.6 Cr | ₹406.98 Cr | ₹283.4 Cr | ₹277.7 Cr | ₹304.56 Cr |
| Cost of Materials Consumed | ₹78.24 Cr | ₹66.14 Cr | ₹65.91 Cr | ₹64.45 Cr | ₹31.77 Cr | ₹0 | ₹0 | ₹0 | ₹128.83 Cr | ₹153.36 Cr | ₹132.77 Cr | ₹146.21 Cr |
| Purchases of Stock-in-Trade | ₹7.26 Cr | ₹9.85 Cr | ₹11.89 Cr | ₹8.66 Cr | ₹33.91 Cr | ₹36.73 Lakh | ₹49.85 Lakh | ₹25.18 Cr | ₹21.2 Cr | ₹1.76 Cr | ₹1.04 Cr | ₹1.34 Cr |
| Changes in Inventories | -₹20.64 Cr | -₹5.86 Cr | -₹56.55 Lakh | -₹1.85 Cr | ₹4.23 Cr | ₹0 | ₹0 | ₹0 | ₹43.96 Cr | -₹9.43 Cr | -₹3.58 Cr | ₹6.11 Cr |
| Employee Benefit Expense | ₹37.2 Cr | ₹31.39 Cr | ₹35.73 Cr | ₹32 Cr | ₹30.79 Cr | ₹6.16 Cr | ₹5.22 Cr | ₹5.56 Cr | ₹38.5 Cr | ₹35.68 Cr | ₹36.42 Cr | ₹38.29 Cr |
| Finance Costs | -₹2.44 Cr | ₹67.36 Lakh | ₹2.01 Cr | ₹1.15 Cr | -₹26.76 Cr | ₹11.36 Lakh | ₹41.08 Lakh | ₹16.87 Lakh | -₹11.48 Cr | ₹21.05 Cr | ₹21.14 Cr | ₹20.38 Cr |
| Depreciation & Amortisation | ₹8.08 Cr | ₹8.84 Cr | ₹6.98 Cr | ₹6.68 Cr | ₹7.44 Cr | ₹24.59 Lakh | ₹21.65 Lakh | ₹24.99 Lakh | ₹12.67 Cr | ₹13.56 Cr | ₹13.19 Cr | ₹13.89 Cr |
| Other Expenses | ₹50.33 Cr | ₹42.56 Cr | ₹35.28 Cr | ₹41.66 Cr | ₹57.51 Cr | ₹3.69 Cr | ₹8.99 Cr | ₹4.25 Cr | ₹76.73 Cr | ₹41.08 Cr | ₹40.25 Cr | ₹47.24 Cr |
| Total Expenses | ₹158.04 Cr | ₹153.59 Cr | ₹157.24 Cr | ₹152.75 Cr | ₹138.89 Cr | ₹10.58 Cr | ₹15.33 Cr | ₹35.41 Cr | ₹310.42 Cr | ₹257.07 Cr | ₹241.23 Cr | ₹273.46 Cr |
| Profit Before Exceptional Items & Tax | ₹16.87 Cr | ₹23.47 Cr | ₹11.06 Cr | ₹9.83 Cr | ₹10.27 Cr | ₹4.64 Cr | ₹31.99 Lakh | ₹6.19 Cr | ₹96.56 Cr | ₹26.33 Cr | ₹36.47 Cr | ₹31.1 Cr |
| Exceptional Items | -₹5.15 Cr | -₹5.85 Cr | ₹0 | ₹0 | ₹215.88 Cr | ₹0 | ₹0 | ₹0 | ₹386.59 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹11.72 Cr | ₹17.61 Cr | ₹11.06 Cr | ₹9.83 Cr | ₹226.15 Cr | ₹4.64 Cr | ₹31.99 Lakh | ₹6.19 Cr | ₹483.15 Cr | ₹26.33 Cr | ₹36.47 Cr | ₹31.1 Cr |
| Total Tax Expense | -₹3.22 Cr | ₹4 Cr | ₹2.3 Cr | ₹1.71 Cr | ₹8.06 Cr | ₹0 | ₹0 | ₹0 | ₹133.56 Cr | ₹4.67 Cr | ₹6.38 Cr | ₹5.43 Cr |
| Net Profit | ₹14.94 Cr | ₹10.74 Cr | ₹8.76 Cr | ₹8.12 Cr | ₹218.09 Cr | ₹4.64 Cr | ₹31.99 Lakh | ₹6.19 Cr | ₹349.59 Cr | ₹21.65 Cr | ₹30.1 Cr | ₹17.05 Cr |
| Other Comprehensive Income | -₹87.45 Lakh | ₹0 | ₹0 | ₹0 | ₹17.23 Cr | ₹0 | ₹0 | ₹0 | ₹2.78 Lakh | ₹0 | -₹37.48 Lakh | ₹0 |
| Total Comprehensive Income | ₹14.06 Cr | ₹10.74 Cr | ₹8.76 Cr | ₹8.12 Cr | ₹235.31 Cr | ₹4.64 Cr | ₹31.99 Lakh | ₹6.19 Cr | ₹349.62 Cr | ₹21.65 Cr | ₹29.72 Cr | ₹17.05 Cr |
| EBITDA (computed) | ₹22.51 Cr | ₹32.98 Cr | ₹20.05 Cr | ₹17.65 Cr | -₹9.05 Cr | ₹5 Cr | ₹94.72 Lakh | ₹6.61 Cr | ₹97.76 Cr | ₹60.94 Cr | ₹70.8 Cr | ₹65.37 Cr |
| Basic EPS | ₹1.79 | ₹1.32 | ₹1.10 | ₹1.18 | ₹32.34 | ₹0.78 | ₹0.05 | ₹1.05 | ₹59.17 | ₹3.66 | ₹5.09 | ₹2.89 |
| Diluted EPS | ₹1.74 | ₹1.27 | ₹1.05 | ₹1.08 | ₹29.51 | ₹0.78 | ₹0.05 | ₹1.05 | ₹59.17 | ₹3.66 | ₹5.09 | ₹2.89 |
Shareholding Pattern of Ind Swift Laboratories Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 42.99%, foreign institutional investors hold 13.88%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 43.12% of Ind Swift Laboratories Limited. The company had 39,222 shareholders on record.
| Mar 2026 | Feb 2026 | Dec 2025 | Sep 2025 | Aug 2025 | Jul 2025 | |
|---|---|---|---|---|---|---|
| Promoters | 42.99% | 43.06% | 39.50% | 39.50% | 37.72% | 36.77% |
| Public | 57.01% | 56.94% | 60.50% | 60.50% | 62.28% | 63.23% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 42.99% | 40.94% | 42.00% | 42.00% | 42.00% | 42.00% | 42.00% | 52.14% | 54.80% | 55.46% | 52.62% |
| Public | 57.01% | 59.06% | 58.00% | 58.00% | 58.00% | 58.00% | 58.00% | 47.86% | 45.20% | 44.54% | 47.38% |
| Promoter change (YoY, %pts) | +2.05 | -1.06 | +0.00 | +0.00 | +0.00 | +0.00 | -10.14 | -2.66 | -0.66 | +2.84 | - |
Board & Governance of Ind Swift Laboratories Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Ind Swift Laboratories Limited has 8 directors - 4 independent and 4 executive. The board is chaired by Navrattan Munjal.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Navrattan Munjal | Executive Director · Chairperson | 1995-01-04 | 1 |
| Himanshu Jain | Executive Director · MD | 2003-07-31 | 1 |
| Rishav Mehta | Executive Director | 2010-03-23 | 1 |
| Sahil Munjal | Executive Director · MD | 2020-02-13 | 1 |
| Neerja Chathley | Non-Executive - Independent Director | 2019-05-10 | 2 |
| Rajinder Kumar Gupta | Non-Executive - Independent Director | 2021-06-23 | 1 |
| Subodh Gupta | Non-Executive - Independent Director | 2025-07-05 | 1 |
| Prabhat Khurana | Non-Executive - Independent Director | 2025-07-05 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Prabhat Khurana (Chairperson), Rajinder Kumar Gupta, Navrattan Munjal |
| Nomination and remuneration committee | Rajinder Kumar Gupta (Chairperson), Subodh Gupta, Neerja Chathley |
| Stakeholders Relationship Committee | Rajinder Kumar Gupta (Chairperson), Navrattan Munjal, Prabhat Khurana |
| Risk Management Committee | Rajinder Kumar Gupta (Chairperson), Navrattan Munjal, Prabhat Khurana |
| Corporate Social Responsibility Committee | Navrattan Munjal (Chairperson), Himanshu Jain, Subodh Gupta |
Group Structure of Ind Swift Laboratories Limited
Ind Swift Laboratories Limited has 2 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Ind Swift Laboratories Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Mjm Remedies Private Limited | U24230CH2022PTC044464 | - |
| Fortune (India) Constructions Limited | U45200CH2005PLC028005 | - |
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Ind Swift Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 May 2026 | Others | ₹1.25 Cr | Open |
| 21 May 2026 | Others | ₹19 Lakh | Open |
| 28 Apr 2026 | Others | ₹28.5 Lakh | Open |
| 23 Mar 2026 | Others | ₹12 Lakh | Open |
| 20 Mar 2026 | Others | ₹74 Lakh | Open |
Total charge records: 104 View all charges
Employees and EPFO Compliance at Ind Swift Laboratories Limited
View historical data on people associated with Ind Swift Laboratories Limited, including employment history and EPFO contributions.
Employee and EPFO history for Ind Swift Laboratories Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Ind Swift Laboratories Limited
GST registrations and filing compliance for Ind Swift Laboratories Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Ind Swift Laboratories Limited
Credit ratings, litigation, and regulatory alerts for Ind Swift Laboratories Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Ind Swift Laboratories Limited
MSME payment history for Ind Swift Laboratories Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Ind Swift Laboratories Limited
Corporate group structure for Ind Swift Laboratories Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Ind Swift Laboratories Limited
MCA filings and documents for Ind Swift Laboratories Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Ind Swift Laboratories Limited
Recent News on Ind Swift Laboratories Limited
Frequently Asked Questions about Ind Swift Laboratories Limited
Ind Swift Laboratories Limited is an active public limited company in the pharma sector based in Chandigarh, Chandigarh, India. It was incorporated on 04 January 1995 (31+ years old) and is registered under CIN L24232CH1995PLC015553. Listed on BSE: 532305 and NSE: INDSWFTLAB.
Ind Swift Laboratories Limited reported revenue of ₹641.29 Cr for FY 2026 (up 14.17% YoY) based on consolidated NSE filings.
The current directors of Ind Swift Laboratories Limited are:
- Rishav Mehta - Whole-Time Director
- Himanshu Jain - Whole-Time Director
- Sahil Munjal - Whole-Time Director
- Neerja Chathley - Director
- Rajinder Kumar Gupta - Director
- Navrattan Munjal - Managing Director
- Subodh Gupta - Director
- Prabhat Khurana - Director
The primary industry of Ind Swift Laboratories Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Ind Swift Laboratories Limited is listed on both BSE (code: 532305) and NSE (symbol: INDSWFTLAB).
Ind Swift Laboratories Limited can be reached at the registered office: Sco 850 Shivalik Enclave Nac Manimajra, Chandigarh, Chandigarh, India – 160101, or through the website indswiftlabs.com.